Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Mehmet ÜnsalDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-9920-6804
Meltem YücesoyDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-5448-8908
Okan OktarDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-9696-7886
Yeşim UçarDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-1957-4202
Gülşah Tiryaki GünerDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0003-4543-1763
Okan AytekinDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-6430-4607
A Alp TokalioğluDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-1776-2744
Hande Esra Koca YildirimDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-3715-9424
Fatih KiliçDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-7333-4883
Burak ErsakDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0003-3301-062X
Caner ÇakirDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0003-2559-9104
Dilek YükselDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-2366-8412
Çiğdem KiliçDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-4433-8068
Sevgi KoçDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-1703-0690
Günsu Kimyon CömertDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0003-0178-4196
Özlem Moraloğlu TekinDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0001-8167-3837
Yaprak Engin ÜstünDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-1011-3848
Taner TuranDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.ORCID https://orcid.org/0000-0001-8120-1143
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Background/aim: Epithelial ovarian cancer is the second most prevalent type of gynecological cancer. We aimed to investigate prognostic factors related to survival in patient with 2014 FIGO stage IIIC high-grade serous ovarian cancer (HGSOC). Materials and methods: Two hundred fifty eight patients were evaluated retrospectively. The absence of a visible tumor was determined as maximum cytoreduction, and a residual tumor size of 1 cm or less was determined as optimal cytoreduction. Patients who underwent cytoreduction followed by a combination of platinum and taxane adjuvant chemotherapy were included. Exclusion criteria for the study were patients taking neoadjuvant chemotherapy and those with suboptimal surgery. Results: Optimal cytoreduction was performed in 107 and maximal cytoreduction was performed in 151 patients. The five-year PFS rate was 27% and the five-year DSS rate was 76%. While high ascites volume and optimal cytoreduction were identified as independent prognostic factors for disease failure, only optimal cytoreduction was an independent prognostic factor for survival. Conclusion: The maximal cytoreduction is improves PFS and DSS in patients with 2014 FIGO stage IIIC HGSOC as our study results. Therefore, maximum surgical effort and radical cytoreductive procedures should be performed.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer who were treated with platin-based adjuvant chemotherapy. · full record | OpenQuestion